How to access Ztalmy from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE family of a child with CDKL5 deficiency disorder (CDD) may receive a prescription for Ztalmy (ganaxolone) from their treating paediatric neurologist. Ztalmy is FDA-approved, manufactured by Marinus Pharmaceuticals, and is an oral suspension neuroactive steroid indicated for seizures associated with CDKL5 deficiency disorder in patients aged 2 years and older. CDKL5 deficiency disorder is a rare, severe, X-linked developmental and epileptic encephalopathy driven by pathogenic variants in the CDKL5 gene. In the UAE, Ztalmy is not locally registered, which is why your paediatric neurologist will navigate the Ministry of Health and Prevention (MoHAP) named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Ztalmy is an oral suspension taken three times daily, dosed by weight. Eligibility is based on clinical diagnosis of CDKL5 deficiency disorder, typically supported by genetic confirmation of a pathogenic variant in CDKL5, with refractory seizures as the primary treatment indication. Treatment requires a paediatric neurologist familiar with developmental and epileptic encephalopathies, with ongoing seizure diary tracking, liver function monitoring, and coordination of concomitant antiseizure medications. Because Ztalmy is oral, in-country administration is straightforward once the prescribing plan is in place.
Is Ztalmy legally importable into the UAE?
Yes — through the MoHAP named-patient import framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the prescribing facility is located.
The named-patient mechanism allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is available, (c) the physician takes clinical responsibility, and (d) chain of custody is documented end to end. For CDKL5 deficiency disorder in the UAE, there is no locally registered disease-specific alternative.
How the pathway works, step by step
- Consultation with your paediatric neurologist. Genetic confirmation of CDKL5 pathogenic variant, clinical diagnosis of CDD, seizure history documentation, and Ztalmy clinical rationale prepared.
- Baseline assessment. Weight, seizure frequency baseline, liver function tests, and current antiseizure regimen documented.
- MoHAP named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, genetic report, patient reference, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Ztalmy from Marinus's authorised distribution channel.
- Shipment. Ztalmy ships with chain-of-custody documentation; manufacturer handling conditions apply during transport.
- Arrival and dispensing. The hospital pharmacy releases the bottle to the family with weight-based dosing instructions and seizure-diary coaching.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming CDD diagnosis, CDKL5 genetic report, baseline seizure profile, current antiseizure regimen, and Ztalmy as the indicated treatment
- Verification of their UAE medical licence
- A copy of the CDKL5 genetic diagnostic report
- Patient identifier (anonymised reference where possible)
- An administration and monitoring plan including weight-based dosing, liver function surveillance, and seizure-diary cadence
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP (or DoH/DHA) reviewers expect to see for rare-paediatric-neurology named-patient imports, including the seizure-diary and liver-function surveillance plan central to Ztalmy.
Costs and timing
Ztalmy is weight-dependent in dosing, so annual cost scales with the child's body weight. Indicative 2026 US cash-pay annual cost sits in a broad range of roughly USD 110,000–250,000 depending on weight. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete MoHAP application is submitted. Refills ship on a rolling basis against the monthly dispensing schedule.
Reserve Meds is in pre-launch. Fulfilment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: CDKL5 deficiency disorder is primarily a condition of girls, and the caregiving journey is typically a multi-year, round-the-clock family effort — mothers, fathers, grandmothers, and paid caregivers often share day and night shifts. In the UAE's expatriate-heavy care environment, care teams often include family in home countries as well. Our concierge coordination supports the extended caregiving network: a designated case lead briefs everyone the primary caregiver nominates, and refill logistics are planned around school schedules and family travel.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Ztalmy specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP (or DoH/DHA) review.
- Logistics. Chain-of-custody shipment coordination to your prescribing hospital pharmacy.
- Concierge case lead. A named point of contact for the family, coordinating long-term refills and weight-based dose adjustments as the child grows.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating paediatric neurologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP (or DoH/DHA) named-patient framework with appropriate documentation. Cross-border named-patient import for rare-paediatric-neurology therapies is a recognised mechanism. See our trust and compliance page.
Is Ztalmy a cure? No. Ztalmy reduces seizure frequency in CDD. It is used alongside — not instead of — the broader antiseizure regimen your neurology team manages. Your paediatric neurologist will discuss realistic outcome expectations.
What side effects should we watch for? Somnolence is the most commonly reported side effect. Your neurologist will coach on dose-titration strategy and monitoring.
Does Ztalmy interact with other antiseizure medications? Yes, drug-interaction review is part of the standard workup. Your neurologist manages the interaction profile.
Will insurance cover this? Cash-pay is the default. Some UAE insurers consider rare-paediatric-neurology imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Ztalmy coordination in the UAE.
Add me to the Ztalmy waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.